BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hao X, Sun G, Zhang Y, Kong X, Rong D, Song J, Tang W, Wang X. Targeting Immune Cells in the Tumor Microenvironment of HCC: New Opportunities and Challenges. Front Cell Dev Biol 2021;9:775462. [PMID: 34869376 DOI: 10.3389/fcell.2021.775462] [Cited by in Crossref: 13] [Cited by in F6Publishing: 19] [Article Influence: 13.0] [Reference Citation Analysis]
Number Citing Articles
1 Han H, Jin W, Li X. Mesenchymal stem cells-based therapy in liver diseases. Mol Biomed 2022;3:23. [DOI: 10.1186/s43556-022-00088-x] [Reference Citation Analysis]
2 Zhang J, Han H, Wang L, Wang W, Yang M, Qin Y. Overcoming the therapeutic resistance of hepatomas by targeting the tumor microenvironment. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.988956] [Reference Citation Analysis]
3 Sarantis P, Trifylli E, Koustas E, Papavassiliou KA, Karamouzis MV, Papavassiliou AG. Immune Microenvironment and Immunotherapeutic Management in Virus-Associated Digestive System Tumors. IJMS 2022;23:13612. [DOI: 10.3390/ijms232113612] [Reference Citation Analysis]
4 Li J, Nie Y, Jia W, Wu W, Song W, Li Y. Effect of Tertiary Lymphoid Structures on Prognosis of Patients with Hepatocellular Carcinoma and Preliminary Exploration of Its Formation Mechanism. Cancers (Basel) 2022;14:5157. [PMID: 36291944 DOI: 10.3390/cancers14205157] [Reference Citation Analysis]
5 Liu B, Liu Z, Feng C, Li C, Zhang H, Li Z, Tu C, He S. Identification of cuproptosis-related lncRNA prognostic signature for osteosarcoma. Front Endocrinol 2022;13:987942. [DOI: 10.3389/fendo.2022.987942] [Reference Citation Analysis]
6 Wang Y, Peng B, Ning C, He S, Yang H, Mao Y, Sun L. Characterization of immune features and immunotherapy response in subtypes of hepatocellular carcinoma based on mitophagy. Front Immunol 2022;13:966167. [DOI: 10.3389/fimmu.2022.966167] [Reference Citation Analysis]
7 Xu X, Xiang Y, Yang Y, Liu K, Cui Z, Tong X, Chen J, Hou F, Luo Z. The application of tumor cell-derived vesicles in oncology therapy. Clin Transl Oncol 2022. [PMID: 36207510 DOI: 10.1007/s12094-022-02966-w] [Reference Citation Analysis]
8 Tang Q, Chen Y, Shen M, Dai W, Liang H, Liu J, Gao J, Yang D. Increased Expression of NXPH4 Correlates with Immune Cell Infiltration and Unfavorable Prognosis in Hepatocellular Carcinoma. Journal of Oncology 2022;2022:1-23. [DOI: 10.1155/2022/5005747] [Reference Citation Analysis]
9 Feng Y, Wu W, Li M. Metal-organic frameworks for hepatocellular carcinoma therapy and mechanism. Front Pharmacol 2022;13:1025780. [DOI: 10.3389/fphar.2022.1025780] [Reference Citation Analysis]
10 Kasprzak A, Adamek A. Role of the Ghrelin System in Colitis and Hepatitis as Risk Factors for Inflammatory-Related Cancers. IJMS 2022;23:11188. [DOI: 10.3390/ijms231911188] [Reference Citation Analysis]
11 Wang H, Shi F, Zheng S, Zhao M, Pan Z, Xiong L, Zheng L. Feasibility of hepatocellular carcinoma treatment based on the tumor microenvironment. Front Oncol 2022;12:896662. [DOI: 10.3389/fonc.2022.896662] [Reference Citation Analysis]
12 Xu Z. Gene mining of immune microenvironment in hepatocellular carcinoma. Medicine 2022;101:e30453. [DOI: 10.1097/md.0000000000030453] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
13 Pu Y, Zhu J, Xu J, Zhang S, Bao Y. Antitumor effect of a polysaccharide from Pseudostellaria heterophylla through reversing tumor-associated macrophages phenotype. Int J Biol Macromol 2022;220:816-26. [PMID: 35988728 DOI: 10.1016/j.ijbiomac.2022.08.111] [Reference Citation Analysis]
14 Peng H, Zhu E, Zhang Y. Advances of cancer-associated fibroblasts in liver cancer. Biomark Res 2022;10:59. [PMID: 35971182 DOI: 10.1186/s40364-022-00406-z] [Reference Citation Analysis]
15 Li R, Zhao W, Liang R, Jin C, Xiong H. Identification and Validation of a Novel Tumor Microenvironment-Related Prognostic Signature of Patients With Hepatocellular Carcinoma. Front Mol Biosci 2022;9:917839. [DOI: 10.3389/fmolb.2022.917839] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Dai L, Tao Y, Shi Z, Liang W, Hu W, Xing Z, Zhou S, Guo X, Fu X, Wang X. SOCS3 Acts as an Onco-immunological Biomarker With Value in Assessing the Tumor Microenvironment, Pathological Staging, Histological Subtypes, Therapeutic Effect, and Prognoses of Several Types of Cancer. Front Oncol 2022;12:881801. [DOI: 10.3389/fonc.2022.881801] [Reference Citation Analysis]
17 Zhu J, Huang Q, Liu S, Peng X, Xue J, Feng T, Huang W, Chen Z, Lai K, Ji Y, Wang M, Yuan R. Construction of a Novel LncRNA Signature Related to Genomic Instability to Predict the Prognosis and Immune Activity of Patients With Hepatocellular Carcinoma. Front Immunol 2022;13:856186. [PMID: 35479067 DOI: 10.3389/fimmu.2022.856186] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Tu B, Gao Y, Sun F, Shi M, Huang Y. Lipid Metabolism Regulation Based on Nanotechnology for Enhancement of Tumor Immunity. Front Pharmacol 2022;13:840440. [PMID: 35392570 DOI: 10.3389/fphar.2022.840440] [Reference Citation Analysis]